公开(公告)号：US06369033B1

公开(公告)日：2002-04-09

申请号：US08953937

申请日：1997-10-20

申请人： Lawrence Steinman ,  Nicholas Ling ,  Paul J. Conlon ,  Amitabh Gaur

发明人： Lawrence Steinman ,  Nicholas Ling ,  Paul J. Conlon ,  Amitabh Gaur

IPC分类号： A61K3810

CPC分类号： C07K14/4713 ,  A61K38/00

摘要： Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.

公开(公告)号：US08835391B2

公开(公告)日：2014-09-16

申请号：US12931001

申请日：2011-01-21

申请人： Lawrence Steinman ,  Shalina Sheryl Ousman ,  William H. Robinson

发明人： Lawrence Steinman ,  Shalina Sheryl Ousman ,  William H. Robinson

IPC分类号： A61K38/00 ,  A61K38/17 ,  A61K31/711

CPC分类号： A61K31/711 ,  A61K38/1709

摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.

摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。

公开(公告)号：US08748404B2

公开(公告)日：2014-06-10

申请号：US12754555

申请日：2010-04-05

申请人： Lawrence Steinman ,  Pedro Ruiz ,  Hideki Garren

发明人： Lawrence Steinman ,  Pedro Ruiz ,  Hideki Garren

IPC分类号： A01N43/04 ,  C12N15/00

CPC分类号： C07K14/62 ,  A01K67/027 ,  A01K2227/105 ,  A01K2267/0325 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/39 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/55527 ,  A61K2039/57

摘要： A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.

摘要翻译： 通过注射到编码与自身免疫疾病相关的自身抗原的DNA的受体中，特异性地抑制促炎T细胞应答。 接受者可以通过与编码Th2细胞因子的DNA（特别是编码IL4）共同接种来进一步治疗。 响应于接种，自身抗原反应性T细胞的增殖和Th1细胞因子（包括IL-2，IFN-γ和IL-15）的分泌减少。

公开(公告)号：US20110243893A1

公开(公告)日：2011-10-06

申请号：US13026173

申请日：2011-02-11

申请人： Robert C. Axtell ,  Lawrence Steinman ,  May H. Han ,  Brigit A. de Jong ,  Chander Raman ,  Michael Walker ,  Jing Shi

发明人： Robert C. Axtell ,  Lawrence Steinman ,  May H. Han ,  Brigit A. de Jong ,  Chander Raman ,  Michael Walker ,  Jing Shi

IPC分类号： A61K38/21 ,  A61K38/02 ,  A61K31/225 ,  A61K39/395 ,  A61P29/00 ,  A61P25/00 ,  G06F19/00

CPC分类号： A61K31/225 ,  A61K31/18 ,  G01N33/6863 ,  G01N33/6896 ,  G01N2333/54 ,  G01N2800/285 ,  Y02A90/26

摘要： Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

摘要翻译： 提供组合物和方法用于炎性疾病的预后分类，例如 炎症性脱髓鞘疾病，患者进入亚型，哪些亚型对患者的治疗需求和对感兴趣的治疗的反应有信息。 细胞因子的模式提供了一种能够识别可能受益于治疗干预的患者的特征模式，并且将具有高反应概率的治疗反应能力高的患者区分开来。 因此，这种签名模式的评估允许改进护理方法。 在本发明的一个实施方案中，自身免疫性疾病是多发性硬化症或神经性脊髓炎。

公开(公告)号：US20070020691A1

公开(公告)日：2007-01-25

申请号：US11491409

申请日：2006-07-21

申请人： Jennifer Kanter ,  William Robinson ,  Lawrence Steinman

发明人： Jennifer Kanter ,  William Robinson ,  Lawrence Steinman

IPC分类号： C12M1/34 ,  G01N33/53

CPC分类号： G01N33/564 ,  G01N2800/24

摘要： To perform large-scale multiplex analysis of lipid-specific binding, lipid microarrays were developed. Lipids identified as disease associated, or analogs there, can be tolerogenic to patients suffering from autoimmune disease. Lipid array analysis has revealed anti-lipid antibodies in patients with immune disorders, and may contribute to the pathogenesis of disease.

摘要翻译： 为了进行脂质特异性结合的大规模多重分析，开发了脂质微阵列。 鉴定为疾病相关的脂质或其类似物可能对患有自身免疫性疾病的患者具有耐受性。 脂质阵列分析揭示了免疫失调患者的抗脂质抗体，可能有助于疾病的发病。

公开(公告)号：US07030098B2

公开(公告)日：2006-04-18

申请号：US09947770

申请日：2001-09-05

申请人： Lawrence Steinman ,  Pedro Ruiz ,  Hideki Garren

发明人： Lawrence Steinman ,  Pedro Ruiz ,  Hideki Garren

IPC分类号： A61K31/70

CPC分类号： C07K14/62 ,  A01K67/027 ,  A01K2227/105 ,  A01K2267/0325 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/39 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/55527 ,  A61K2039/57

摘要： A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.

公开(公告)号：US20050119204A1

公开(公告)日：2005-06-02

申请号：US10495893

申请日：2002-11-21

申请人： Dorothee Chabas ,  Lawrence Steinman

发明人： Dorothee Chabas ,  Lawrence Steinman

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K48/00 ,  A61P1/16 ,  A61P3/10 ,  A61P5/00 ,  A61P19/02 ,  A61P25/08 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P31/22 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  C07K14/52 ,  C12Q1/68 ,  G01N33/567

CPC分类号： C07K14/52 ,  A61K48/00

摘要： This invention provides a method for reducing the amount of osteopontin in an osteopontin-expressing cell comprising introducing into the cell a nucleic acid which specifically inhibits osteopontin expression in the cell. This invention also provides methods for inhibiting the onset of, and treating, osteopontin-related disorders, as well as compositions for practicing the same. This invention further provides methods for determining the amount of osteopontin in a sample, and a kit for practicing the same. This invention also provides methods for determining whether an agent reduces the amount of osteopontin in an osteopontin-expressing cell. Finally, this invention provides methods for treating a subject afflicted with a disorder mediated by an endogenous protein.

摘要翻译： 本发明提供减少骨桥蛋白表达细胞中骨桥蛋白含量的方法，包括向细胞内引入特异性抑制细胞中骨桥蛋白表达的核酸。 本发明还提供了抑制骨桥蛋白相关疾病的发生和治疗以及用于实践它们的组合物的方法。 本发明还提供了用于测定样品中骨桥蛋白含量的方法，以及用于实施其的试剂盒。 本发明还提供了用于确定试剂是否降低骨桥蛋白表达细胞中骨桥蛋白含量的方法。 最后，本发明提供了治疗受内源性蛋白质介导的病症折磨的受试者的方法。

公开(公告)号：US06794414B1

公开(公告)日：2004-09-21

申请号：US09719770

申请日：2001-09-06

申请人： Lawrence Steinman

发明人： Lawrence Steinman

IPC分类号： A61K3113

CPC分类号： C12N9/1044 ,  A61K38/00

摘要： Diseases Mediated by transglutaminase, such as Huntington's Disease, spinobulbar atrophy, spinocerebellar ataxia, and dentatorubralpallidoluysian atrophy, as well as inflammatory diseases of the central nervous system, including mautiple sclerosis, rheumatoid arthritis, and insulin dependent diabetes mellitus, can be treated by administering a transglutaminase inhibitor such as monadansyl cadaverine, monoamines and diamines such as cystamine, putrescine, GABA. (gamma-amino benzoic acid), N-benzyloxy carbonyl, 5-deazp-4-oxonorvaline p-nitrophenylester, glycine methyl ester, CuSO4, and the oral anti-hyperglycemic agent tolbutamide.

摘要翻译： 转谷氨酰胺酶介导的疾病，如亨廷顿舞蹈症，旋涡异常萎缩，脊髓小脑性共济失调和牙周炎性萎缩性萎缩，以及中枢神经系统炎症性疾病，包括轻度硬化，类风湿性关节炎和胰岛素依赖性糖尿病，均可通过给予 转谷氨酰胺酶抑制剂如单降糖基尸胺，单胺和二胺如胱胺，腐胺，GABA。 （γ-氨基苯甲酸），N-苄氧羰基，5-脱氮-4-氧基缬氨酸对硝基苯酯，甘氨酸甲酯，CuSO 4和口服抗高血糖剂甲苯磺丁脲。

公开(公告)号：US06531130B1

公开(公告)日：2003-03-11

申请号：US09606254

申请日：2000-06-28

申请人： Lawrence Steinman ,  Pedro José Ruiz

发明人： Lawrence Steinman ,  Pedro José Ruiz

IPC分类号： A61K3900

CPC分类号： C07K14/4713 ,  A61K38/02 ,  A61K39/00

摘要： Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of an ordered peptide comprising a repeated motif {SEQ ID NO: 1} [1E2Y3Y4K]n, where n is from 2 to 6. Some specific peptides of interest include those having the sequence {SEQ ID NO: 4} EYYKEYYKEYYK. The peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other amino acid residues. For therapy, the peptides may be administered topically or parenterally, e.g. by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. In a preferred embodiment, subcutaneous injection is used to deliver the peptide. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, e.g. immunosuppressants, &bgr;-interferon, steroids, etc.

摘要翻译： 提供组合物和方法用于治疗脱髓鞘性自身免疫性疾病。 给予治疗剂量，其包含重复基序（SEQ ID NO：1）[1E2Y3Y4K] n，其中n为2至6的有序肽。一些特定的目标肽包括具有序列{SEQ ID NO：4} EYYKEYYYYYKK 。 肽可以仅由有序重复组成，或者可以通过加入其它氨基酸残基在任一末端延伸。 对于治疗，肽可以局部或肠胃外给药，例如， 通过在特定部位注射，包括皮下，腹膜内，血管内等或通过电转运进行皮下注射。 在优选的实施方案中，皮下注射用于递送肽。 本发明方法用于预防或治疗目的。 本发明的组合物还可以含有其它治疗活性剂，例如， 免疫抑制剂，β-干扰素，类固醇等

公开(公告)号：US5532265A

公开(公告)日：1996-07-02

申请号：US348262

申请日：1994-11-30

申请人： Koenraad Gijbels ,  Lawrence Steinman

发明人： Koenraad Gijbels ,  Lawrence Steinman

IPC分类号： A61K31/405 ,  A61K38/06 ,  A61K38/55

CPC分类号： A61K38/06 ,  A61K31/405 ,  A61K38/55

摘要： A synthetic inhibitor of matrix metalloproteases, the tripeptide hydroxamate GM 6001, is administered to a patient suffering from an inflammatory disease of the central nervous system wherein the effect is mediated primarily through restoration of the blood-CNS barrier.

摘要翻译： 对患有中枢神经系统炎性疾病的患者施用基质金属蛋白酶合成抑制剂三肟异羟肟酸GM 6001，其中该作用主要通过恢复血液中枢神经系统屏障而介导。